Literature DB >> 22354318

Intravenous immunoglobulin prevents release of proinflammatory cytokines in human monocytic cells stimulated with procalcitonin.

Kazuki Murakami1, Chiaki Suzuki, Akihiro Fujii, Teruaki Imada.   

Abstract

OBJECTIVE: The aim of this study was to investigate whether the stimulation of monocytic cells with procalcitonin (PCT) results in the release of proinflammatory cytokines. The effects of intravenous immunoglobulin (IVIG) on the production of cytokines from the cells stimulated with PCT were also studied.
MATERIALS AND METHODS: Cultured monocytic cells [THP-1 cells treated with phorbol myristate acetate or peripheral blood mononuclear cells (PBMCs)] were stimulated with PCT. The protein levels of proinflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and high mobility group box-1] in the culture supernatants were determined by ELISA kits. The concentration of PCT-specific IgG antibody in IVIG was measured using a specific ELISA.
RESULTS: PCT induced the release of cytokines from THP-1 cells in a time- and dose-dependent manner. IVIG inhibited the release of cytokines from the cells stimulated with PCT. It was confirmed that IVIG also inhibited TNF-α release in the same dose range for PBMCs stimulated with PCT. The presence of PCT-specific IgG antibody was detected in the tested IVIG, which might be one of the mechanisms.
CONCLUSIONS: PCT induced the release of proinflammatory cytokines from THP-1 cells and PBMCs. The function of PCT was prevented by the presence of IVIG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354318     DOI: 10.1007/s00011-012-0452-8

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  21 in total

Review 1.  Physiology and genetics of procalcitonin.

Authors:  P Maruna; K Nedelníková; R Gürlich
Journal:  Physiol Res       Date:  2000       Impact factor: 1.881

2.  Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs.

Authors:  Kristin E Wagner; Jose M Martinez; Steven D Vath; Richard H Snider; Eric S Nylén; Kenneth L Becker; Beat Müller; Jon C White
Journal:  Crit Care Med       Date:  2002-10       Impact factor: 7.598

Review 3.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors.

Authors:  K L Becker; E S Nylén; J C White; B Müller; R H Snider
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

4.  Optimized THP-1 differentiation is required for the detection of responses to weak stimuli.

Authors:  E K Park; H S Jung; H I Yang; M C Yoo; C Kim; K S Kim
Journal:  Inflamm Res       Date:  2007-01       Impact factor: 4.575

5.  Exogenous procalcitonin evokes a pro-inflammatory cytokine response.

Authors:  Angelike P Liappis; Kevin W Gibbs; Eric S Nylen; Bona Yoon; Richard H Snider; Baochong Gao; Kenneth L Becker
Journal:  Inflamm Res       Date:  2010-10-17       Impact factor: 4.575

Review 6.  Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses.

Authors:  P M Schlievert
Journal:  J Allergy Clin Immunol       Date:  2001-10       Impact factor: 10.793

7.  Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?

Authors:  Evangelos J Giamarellos-Bourboulis; Anna Mega; Paraskevi Grecka; Nektaria Scarpa; George Koratzanis; George Thomopoulos; Helen Giamarellou
Journal:  Intensive Care Med       Date:  2002-08-07       Impact factor: 17.440

Review 8.  Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock.

Authors:  K Georg Kreymann; Geraldine de Heer; Axel Nierhaus; Stefan Kluge
Journal:  Crit Care Med       Date:  2007-12       Impact factor: 7.598

9.  Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis.

Authors:  E S Nylen; K T Whang; R H Snider; P M Steinwald; J C White; K L Becker
Journal:  Crit Care Med       Date:  1998-06       Impact factor: 7.598

10.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors:  M Pollack
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

View more
  4 in total

Review 1.  Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.

Authors:  Benjamin M Liu; Harry R Hill
Journal:  J Interferon Cytokine Res       Date:  2020-12       Impact factor: 2.607

2.  Intravenous immunoglobulin preparation prevents the production of pro-inflammatory cytokines by modulating NFκB and MAPKs pathways in the human monocytic THP-1 cells stimulated with procalcitonin.

Authors:  Kazuki Murakami; Chiaki Suzuki; Akihiro Fujii; Fujio Kobayashi; Atsushi Nakano; Akihito Kamizono
Journal:  Inflamm Res       Date:  2014-05-29       Impact factor: 4.575

3.  Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.

Authors:  Lakshman Puli; Yuriy Pomeshchik; Katja Olas; Tarja Malm; Jari Koistinaho; Heikki Tanila
Journal:  J Neuroinflammation       Date:  2012-05-29       Impact factor: 8.322

Review 4.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.